In a study of 60 patients with non-A, non-B/type C (NANB/C) chronic hepatitis alanine aminotransferase (ALT) activities returned to normal after treatment with interferon alfa-2b (3 million units for six months) in 70.7% and 29-3% did not respond. The response was maintained during four to six months, follow up in 41-4% of patients. Liver biopsy specimen showed histological improvement in all patients surveyed. Treatment was well tolerated with only mild side effects. (Gut 1993; supplement: S126) 
Abstract
In a study of 60 patients with non-A, non-B/type C (NANB/C) chronic hepatitis alanine aminotransferase (ALT) activities returned to normal after treatment with interferon alfa-2b (3 million units for six months) in 70.7% and 29-3% did not respond. The response was maintained during four to six months, follow up in 41-4% of patients. Liver biopsy specimen showed histological improvement in all patients surveyed. Treatment was well tolerated with only mild side effects. (Gut 1993; supplement: S126) In this paper, we present the results of a study of recombinant interferon alfa-2b treatment in 60 patients with chronic non-A, non-B/type C (NANB/C) hepatitis, 57 of whom were positive for antibodies to hepatitis C virus (anti-HCV). 
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